Inhibition of respiratory viruses by nasally administered siRNA

No abstract is available for this paper.

• Publication year

  2005

• Venue

  Nature Medicine

• Publication date

  Unknown publication date

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/nm1164PMID 15619632
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Control of nonsegmented negative-strand RNA virus replication by siRNA.

  2004cited by this paper
• Animal Pneumoviruses: Molecular Genetics and Pathogenesis

  2004cited by this paper
• The RNAi revolution

  2004cited by this paper
• Protection against lethal influenza virus challenge by RNA interference in vivo.

  2004cited by this paper
• Sequence-Specific Inhibition of Small RNA Function

  2004cited by this paper
• Rational siRNA design for RNA interference

  2004cited by this paper
• New drugs and treatment for respiratory syncytial virus

  2004cited by this paper
• Inhibition of influenza virus production in virus-infected mice by RNA interference.

  2004cited by this paper
• Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase

  2004cited by this paper
• Simultaneous detection of fourteen respiratory viruses in clinical specimens by two multiplex reverse transcription nested‐PCR assays

  2004cited by this paper
• Human Immunodeficiency Virus Type 1 Escapes from RNA Interference-Mediated Inhibition

  2004cited by this paper
• Specific inhibition of type I interferon signal transduction by respiratory syncytial virus.

  2004cited by this paper
• Nonspecific, concentration-dependent stimulation and repression of mammalian gene expression by small interfering RNAs (siRNAs).

  2004cited by this paper
• Asymmetry in the assembly of the RNAi enzyme complex.

  2003cited by this paper
• Functional siRNAs and miRNAs exhibit strand bias.

  2003cited by this paper
• Activation of the interferon system by short-interfering RNAs

  2003cited by this paper
• RNA interference targeting Fas protects mice from fulminant hepatitis

  2003cited by this paper
• Bovine parainfluenza virus type 3 (PIV3) expressing the respiratory syncytial virus (RSV) attachment and fusion proteins protects hamsters from challenge with human PIV3 and RSV.

  2003cited by this paper
• Expression profiling reveals off-target gene regulation by RNAi

  2003cited by this paper
• Induction of an interferon response by RNAi vectors in mammalian cells

  2003cited by this paper
• Asymmetry in the Assembly of the RNAi Enzyme Complex

  2003cited by this paper
• Inhibition of hepatitis B virus in mice by RNA interference

  2003cited by this paper
• The Complex Relationship between Respiratory Syncytial Virus and Allergy in Lung Disease

  2003cited by this paper
• Zileuton reduces respiratory illness and lung inflammation, during respiratory syncytial virus infection, in mice.

  2003cited by this paper
• Enhanced Disease and Pulmonary Eosinophilia Associated with Formalin-Inactivated Respiratory Syncytial Virus Vaccination Are Linked to G Glycoprotein CX3C-CX3CR1 Interaction and Expression of Substance P

  2003cited by this paper
• Structural characterization of respiratory syncytial virus fusion inhibitor escape mutants: homology model of the F protein and a syncytium formation assay.

  2003cited by this paper
• Potential therapeutic implications of new insights into respiratory syncytial virus disease

  2002cited by this paper
• The Role of IFN in Respiratory Syncytial Virus Pathogenesis

  2002cited by this paper
• A Role for Immune Complexes in Enhanced Respiratory Syncytial Virus Disease

  2002cited by this paper
• RSV entry inhibitors block F-protein mediated fusion with model membranes.

  2002cited by this paper
• MicroRNAs in plants.

  2002cited by this paper
• Inducible Expression of Inflammatory Chemokines in Respiratory Syncytial Virus-Infected Mice: Role of MIP-1α in Lung Pathology

  2001cited by this paper
• Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses

  2001cited by this paper
• Phosphatidylcholine molecular species in lung surfactant: composition in relation to respiratory rate and lung development.

  2001cited by this paper
• Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells

  2001cited by this paper
• Recombinant Bovine/Human Parainfluenza Virus Type 3 (B/HPIV3) Expressing the Respiratory Syncytial Virus (RSV) G and F Proteins Can Be Used To Achieve Simultaneous Mucosal Immunization against RSV and HPIV3

  2001cited by this paper
• Profilin Is Required for Optimal Actin-Dependent Transcription of Respiratory Syncytial Virus Genome RNA

  2000cited by this paper
• Respiratory syncytial virus genetic and antigenic diversity.

  2000cited by this paper
• Bovine Respiratory Syncytial Virus Nonstructural Proteins NS1 and NS2 Cooperatively Antagonize Alpha/Beta Interferon-Induced Antiviral Response

  2000cited by this paper
• African green monkeys provide a useful nonhuman primate model for the study of human parainfluenza virus types-1, -2, and -3 infection.

  2000cited by this paper
• Role of cellular actin in the gene expression and morphogenesis of human respiratory syncytial virus.

  1998cited by this paper
• Involvement of Actin Microfilaments in the Replication of Human Parainfluenza Virus Type 3

  1998cited by this paper
• Respiratory syncytial virus affects pulmonary function in BALB/c mice.

  1998cited by this paper
• Primary respiratory syncytial virus infection in mice

  1988cited by this paper
• The Release of Leukotrienes in the Respiratory Tract during Infection with Respiratory Syncytial Virus: Role in Obstructive Airway Disease

  1988cited by this paper
• Respiratory syncytial virus. I. Concentration and purification of the infectious virus.

  1978cited by this paper

• Recent Advances in Lipid Nanoparticles: Nucleic Acid Therapeutics and Targeting Strategies.

  2025cites this paper
• Regulation of viral replication by host restriction factors

  2025cites this paper
• The role of PD-L1 gene silencing on growth, migration, and apoptosis in oral squamous carcinoma cell line HN-5

  2025cites this paper
• Inhaled non-viral delivery systems for RNA therapeutics

  2025cites this paper
• Potential Broad-Spectrum Antiviral Agents: A Key Arsenal Against Newly Emerging and Reemerging Respiratory RNA Viruses

  2025cites this paper
• Development of Inhaled Dry Powder Formulations for Naked Nucleic Acids 
without Transfection Agents

  2025cites this paper
• Respiratory Delivery of Highly Conserved Antiviral siRNAs Suppress SARS-CoV-2 Infection

  2025cites this paper
• Advances in development of antiviral strategies against respiratory syncytial virus

  2025cites this paper
• Preclinical testing of antiviral siRNA therapeutics delivered in lipid nanoparticles in animal models – a comprehensive review

  2025cites this paper
• Delivery strategies for RNA-targeting therapeutic nucleic acids and RNA-based vaccines against respiratory RNA viruses: IAV, SARS-CoV-2, RSV

  2025cites this paper
• Optimizing RSV Treatment: Insights into Targeted Drug Delivery Strategies and Public Health Implications

  2025cites this paper
• RNAi-mediated inhibition of SARS-CoV-2: applications and challenges

  2024cites this paper
• Nemo mRNA vaccination improves airway barrier function in mice with airway allergy.

  2024cites this paper
• Principle, application and challenges of development siRNA-based therapeutics against bacterial and viral infections: a comprehensive review

  2024cites this paper
• SiRNAs as antiviral drugs - Current status, therapeutic potential and challenges.

  2024cites this paper
• RNA therapeutics for respiratory diseases.

  2024cites this paper
• Intranasal antivirals against respiratory syncytial virus: the current therapeutic development landscape

  2024influential citation
• siRNA-Based Novel Therapeutic Strategies to Improve Effectiveness of Antivirals: An Insight

  2023cites this paper
• Nanostructures for prevention, diagnosis, and treatment of viral respiratory infections: from influenza virus to SARS-CoV-2 variants

  2023cites this paper
• Where should siRNAs go: applicable organs for siRNA drugs

  2023cites this paper
• Remodeling the tumor immune microenvironment via siRNA therapy for precision cancer treatment

  2023cites this paper
• Multidrug resistance protein 1 silencing in osteosarcoma and chondrosarcoma cell lines

  2023cites this paper
• Current and emerging pharmacotherapy for respiratory syncytial virus (RSV) infection in infants

  2023cites this paper
• Innate immune regulations and various siRNA modalities

  2023cites this paper
• Prophylactic intranasal administration of lipid nanoparticle formulated siRNAs reduce SARS-CoV-2 and RSV lung infection

  2023cites this paper
• Stability of Naked Nucleic Acids under Physical Treatment and Powder Formation: Suitability for Development as Dry Powder Formulations for Inhalation

  2023cites this paper
• Cryo-EM structure of the nucleocapsid-like assembly of respiratory syncytial virus

  2023cites this paper
• Antiviral and protective effect of small interfering RNAs against rift valley fever virus in vitro

  2023cites this paper
• New insights from nanotechnology in SARS-CoV-2 detection, treatment strategy, and prevention

  2023cites this paper
• New insights from nanotechnology in SARS-CoV-2 detection , treatment strategy and 2 prevention 3

  2023cites this paper
• Pulmonary Delivery for miRs: Present and Future Potential

  2023cites this paper
• Specificity of oligonucleotide gene therapy (OGT) agents

  2022cites this paper
• A model system for antiviral siRNA therapeutics using exosome-based delivery

  2022cites this paper
• The Promising Therapeutic Potential of Oligonucleotides for Pulmonary Fibrotic Diseases

  2022cites this paper
• Nebulization of siRNA for inhalation therapy based on a microfluidic surface acoustic wave platform

  2022cites this paper
• A siRNA targets and inhibits a broad range of SARS‐CoV‐2 infections including Delta variant

  2022cites this paper
• Intranasal delivery of lipid nanoparticle encapsulated SARS-CoV-2 and RSV-targeting siRNAs reduces lung infection

  2022cites this paper
• Inhaled siRNA Formulations for Respiratory Diseases: From Basic Research to Clinical Application

  2022cites this paper
• Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases

  2022cites this paper
• Effect of the array of amines on the transfection efficiency of cationic peptidomimetic lipid molecules into neural cells

  2022cites this paper
• A Comprehensive Review on the Current Vaccines and Their Efficacies to Combat SARS-CoV-2 Variants

  2022cites this paper
• RNA interference targeting UL25 gene as a gene therapy approach against BHV-1.

  2022cites this paper
• RNAi to treat SARS‐CoV‐2—variant proofing the next generation of therapies

  2022cites this paper
• A polyA DNA probe-based ultra-sensitive and structure-distinguishable electrochemical biosensor for the analysis of RNAi transgenic maize.

  2021cites this paper
• Молекулярные и клеточные механизмы патогенеза респираторно-синцитиальной вирусной инфекции. Новые данные на экспериментальных моделях

  2021cites this paper
• Recent Advances in Nanocarriers Used for Selective Gene Silencing Therapy

  2021cites this paper
• Reciprocal regulation of RIG-I and XRCC4 connects DNA repair with RIG-I immune signaling

  2021cites this paper
• Correction

  2021cites this paper
• Extension in the approaches to treat cancer through siRNA system: a beacon of hope in cancer therapy

  2021cites this paper
• The mixture of siRNAs targeted to IL-4 and IL-13 genes effectively reduces the airway hyperreactivity and allergic inflammation in a mouse model of asthma.

  2021cites this paper
• Therapeutic based on small interfering RNA (siRNA)

  2021cites this paper
• Poly(lactide-co-glycolide) Nanoparticles Mediate Sustained Gene Silencing and Improved Biocompatibility of siRNA Delivery Systems in Mouse Lungs after Pulmonary Administration.

  2021cites this paper
• Silencing of SARS‐CoV‐2 with modified siRNA‐peptide dendrimer formulation

  2021cites this paper
• Nanoparticles for local delivery of siRNA in lung therapy.

  2021cites this paper
• Modulation of intrinsic inhibitory checkpoints using nano‐carriers to unleash NK cell activity

  2021cites this paper
• Antisense Oligonucleotide-Based Therapy of Viral Infections

  2021cites this paper
• Inhibition of SARS-CoV-2 Replication by a Small Interfering RNA Targeting the Leader Sequence

  2021cites this paper
• Specific delivering of RNAi using Spike's aptamer‐functionalized lipid nanoparticles for targeting SARS‐CoV‐2: A strong anti‐Covid drug in a clinical case study

  2021cites this paper
• Molecular and Cellular Mechanisms of Respiratory Syncytial Viral Infection: Using Murine Models to Understand Human Pathology

  2021cites this paper
• shRNA transgenic swine display resistance to infection with the foot-and-mouth disease virus

  2021cites this paper
• Inhibition of autophagy promotes human RSV NS1-induced inflammation and apoptosis in vitro

  2021cites this paper
• Nucleic Acid Delivery for Therapeutic Applications.

  2021cites this paper
• Reciprocal regulation of RIG-I and XRCC4 connects DNA repair with RIG-I immune signaling

  2021cites this paper
• Novel RNA Interference (RNAi)-Based Nanomedicines for Treating Viral Infections

  2021cites this paper
• siRNA Therapeutics against Respiratory Viral Infections—What Have We Learned for Potential COVID‐19 Therapies?

  2021cites this paper
• Delivery of small interfering RNAs by nanovesicles for cancer therapy.

  2021cites this paper
• Osteopontin silencing attenuates bleomycin-induced murine pulmonary fibrosis by regulating epithelial-mesenchymal transition.

  2021cites this paper
• The Uniqueness of Tryptophan in Biology: Properties, Metabolism, Interactions and Localization in Proteins

  2020cites this paper
• COVID-19: A Global Challenge with Old History, Epidemiology and Progress So Far

  2020cites this paper
• Multi-targeted gene silencing strategies inhibit replication of Canine morbillivirus

  2020cites this paper
• A multifunctional nanoparticle as a prophylactic and therapeutic approach targeting respiratory syncytial virus.

  2020cites this paper
• Aptamer-Protamine-siRNA nanoparticles in targeted therapy of ErbB3 positive breast cancer cells.

  2020cites this paper
• Nanoparticles‐assisted delivery of antiviral‐siRNA as inhalable treatment for human respiratory viruses: A candidate approach against SARS‐COV‐2

  2020cites this paper
• Modification of KL4 Peptide Revealed the Importance of Alpha-Helical Structure for Efficient siRNA Delivery

  2020influential citation
• Cloaked Viruses and Viral Factors in Cutting Edge Exosome-Based Therapies

  2020cites this paper
• Present Situation and Future Progress of Inhaled Lung Cancer Therapy: Necessity of Inhaled Formulations with Drug Delivery Functions.

  2020cites this paper
• Recent advances in siRNA delivery mediated by lipid-based nanoparticles

  2020cites this paper
• Current trends in targeted therapy for drug-resistant infections

  2019cites this paper
• The potential of siRNA based drug delivery in respiratory disorders: Recent advances and progress

  2019cites this paper
• Slicing and dicing viruses: antiviral RNA interference in mammals

  2019cites this paper
• Applications of Lipidic and Polymeric Nanoparticles for siRNA Delivery

  2019cites this paper
• Biodistribution/biostability assessment of siRNA after intravenous and intratracheal administration to mice, based on comprehensive analysis of in vivo/ex vivo/polyacrylamide gel electrophoresis fluorescence imaging.

  2019cites this paper
• Nanocarriers in effective pulmonary delivery of siRNA: current approaches and challenges.

  2019cites this paper
• siRNA-Mediated Simultaneous Regulation of the Cellular Innate Immune Response and Human Respiratory Syncytial Virus Replication

  2019influential citation
• Clinical advances of siRNA therapeutics

  2019cites this paper
• PrPC knockdown by liposome-siRNA-peptide complexes (LSPCs) prolongs survival and normal behavior of prion-infected mice immunotolerant to treatment

  2019cites this paper
• siRNA Delivery Technology for Cancer Therapy: Promise and Challenges

  2019cites this paper
• Design, mechanism, delivery and therapeutics of canonical and Dicer-substrate siRNA

  2019cites this paper
• Tumor Chemosensitization through Oncogene Knockdown Mediated by Unique α-Tocopherylated Cationic Geminis.

  2019cites this paper
• Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes.

  2019cites this paper
• Ex vivo dendritic cell generation-A critical comparison of current approaches.

  2019cites this paper
• Intratracheal Administration of siRNA Triggers mRNA Silencing in the Lung to Modulate T Cell Immune Response and Lung Inflammation

  2019cites this paper
• PRECISION-CUT LUNG SLICES IN FIBROSIS RESEARCH

  2019cites this paper
• A New Approach to the Development of an RSV Anti-viral Targeted Nanocarrier for Dual Inhibition of Viral Infection and Replication

  2018influential citation
• Therapeutic Potency of Nanoformulations of siRNAs and shRNAs in Animal Models of Cancers

  2018cites this paper
• Recent Advances in RNA Therapeutics and RNA Delivery Systems Based on Nanoparticles

  2018cites this paper
• Advancements in Nucleic Acid Based Therapeutics against Respiratory Viral Infections

  2018cites this paper
• Aptamer-iRNAs as Therapeutics for Cancer Treatment

  2018cites this paper
• The Mechanism for siRNA Transmembrane Assisted by PMAL

  2018cites this paper
• RNAi-mediated antiviral immunity in mammals.

  2018cites this paper